Loading...
•
Sep 30, 2023
Maravai Q3 2023 Earnings Report
Maravai reported a decrease in revenue due to reduced demand for COVID-19 related products and a weak industry environment, while implementing cost realignment initiatives.
Key Takeaways
Maravai LifeSciences reported a 65% decrease in revenue for Q3 2023, driven by a significant drop in Nucleic Acid Production revenue due to lower COVID-19 related CleanCap demand and customer capital conservation efforts. The company is implementing a cost realignment initiative targeting $30 million in annualized cost reductions, including a workforce reduction of approximately 15%.
Q3 revenue was $66.9 million, a 65% decrease year-over-year.
Net loss was $(15.1) million, compared to net income of $99.7 million in the same period last year.
The company is implementing a cost realignment initiative targeting at least $30 million in annualized cost reductions, including a workforce reduction of approximately 15%.
Updated financial guidance for the full year 2023 projects revenue in the range of $275.0 million to $285.0 million.
Revenue by Segment
Forward Guidance
Maravai anticipates full year 2023 revenue to be between $275.0 million and $285.0 million.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...